A peer-reviewed reading of the thymosin alpha-1 record.

The short version

Thymosin alpha-1 (Tα1) is a 28-amino acid peptide the thymus produces naturally — and one with an unusually deep clinical research record. Over five decades it has been tested in more than 30 randomized controlled trials across hepatitis B and C, severe sepsis, cancer immunotherapy, pancreatitis, and COVID-19, enrolling more than 11,000 participants. The synthetic version, thymalfasin, is approved as a pharmaceutical in roughly 35 countries. It is not approved by the FDA for any indication in the United States. In plain terms: it trains immune cells called dendritic cells to alert the rest of the immune system more effectively, shifting the response toward the pathogen-fighting mode while also carrying a counterbalancing regulatory arm. The evidence is strongest in chronic viral hepatitis; the large 2025 sepsis trial came back null. What people experience on it, and the cited cautions — see the effects page.

What is Thymosin Alpha-1?

Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide produced endogenously in the thymus. It was first isolated from bovine thymus fraction 5 by Goldstein and colleagues in 1977 ^[1] and has since been characterized as a regulator of T cell maturation and innate-adaptive immune coordination. The N-terminal acetylation is essential for biological activity; without it, the peptide does not bind its primary targets.

Tα1 is derived by cleavage of prothymosin alpha (ProTα), a 113-amino acid precursor, by the lysosomal enzyme legumain. It has a molecular weight of 3,108 daltons. The synthetic form — thymalfasin — has been approved as a pharmaceutical in approximately 35 countries for chronic hepatitis B and as an immune adjuvant in oncology. It is not approved by the United States Food and Drug Administration for any indication.

In 2023, the FDA placed thymosin alpha-1 on its Category 2 bulk drug substances list, restricting its production by 503A and 503B compounding pharmacies in the US. This regulatory action has been challenged in the peer-reviewed literature. A 2024 comprehensive review of the clinical evidence base ^[12] characterized the restriction as 'unfounded' given the available safety and efficacy data across more than 30 trials and 11,000 human subjects.

The compound is not a supplement, a growth factor, or a hormone. It is an endogenous immunomodulatory peptide — one whose clinical research record spans nearly five decades and multiple indications.

What the Research Shows

The Tα1 research record divides into four primary indication areas: chronic viral hepatitis (the founding clinical indication), severe sepsis and critical illness, oncology and immune checkpoint synergy, and aging and immunosenescence.

In hepatitis B, a six-month regimen studied at 1.6 mg subcutaneous twice weekly produced a 48.3% complete response rate at follow-up versus 27.3% for interferon-alpha monotherapy, with markedly superior tolerability ^[3]. In hepatitis C, the combination of Tα1 plus interferon-alpha produced biochemical response rates of 37.1% versus 16.2% for interferon alone in a randomized placebo-controlled trial ^[2].

In sepsis, the ETASS multicenter trial ^[6] — 361 patients across six Chinese tertiary hospitals — reported a 28-day mortality reduction from 35.0% to 26.0% (log-rank P = 0.049) alongside significant improvements in monocyte HLA-DR expression, a validated marker of immune paralysis reversal. However, the 2025 TESTS phase 3 trial ^[16] — the largest double-blind, randomized study to date (n = 1,106 patients, 22 centers) — found no significant reduction in 28-day all-cause mortality (23.4% vs 24.1%; HR 0.99, P = 0.93). The discrepancy between these findings is the central unresolved question in the Tα1 sepsis literature.

In oncology, retrospective data from patients with metastatic melanoma who received sequential Tα1 followed by anti-CTLA-4 therapy showed a median overall survival of 57.8 months versus 7.4 months in non-sequentially treated patients ^[10]. These findings are hypothesis-generating; prospective confirmatory trials have not yet been completed.

A 2025 review of Tα1 and aging ^[17] documented antioxidant protection of thymic epithelial cells, reduction of proinflammatory cytokines (TNFα, IL-1β, IL-6), and improved vaccine responses in elderly populations — connecting the compound's mechanism to the thymic involution that underlies immunosenescence.

Mechanism: TLR2, TLR9, and Dendritic Cell Activation

Thymosin alpha-1 acts by binding Toll-like receptors TLR2 and TLR9 on dendritic cells, triggering their maturation and IL-12 production via p38 MAPK and NF-κB signaling pathways ^[5]. The downstream consequences are measurable: CD4+ T cells differentiate toward a Th1 effector phenotype secreting IFN-γ and IL-2, CD8+ cytotoxic T lymphocytes expand, and natural killer cell activity increases.

In sepsis, the pharmacodynamic marker of interest is monocyte HLA-DR expression. Suppressed HLA-DR — the state termed immune paralysis — is a hallmark of sepsis-induced immunosuppression and a predictor of secondary infections and mortality. In the ETASS trial, Tα1 produced statistically significant improvements in HLA-DR expression at both day 3 (+3.9%, P = 0.037) and day 7 (+5.8%, P = 0.017) ^[6]. This biological signal has been consistent across mechanistic studies; the question that remains open is whether that signal translates into a mortality benefit in large-scale heterogeneous populations.

In the cancer context, an additional pathway has been described: Tα1 activates IDO1-dependent tolerogenic signaling, which in murine models protects against immune checkpoint inhibitor-induced colitis while preserving anti-tumor immune responses ^[9]. This dual function — immunostimulatory in the tumor-immune axis, immunomodulatory in gut pathology — is the rationale for the checkpoint inhibitor sequential studies.

Where to Go From Here

This site organizes the Tα1 evidence record into five content areas beyond this overview. The evidence page covers mechanism, clinical trials, and the ETASS-versus-TESTS contested finding in depth. The dosage page documents the research-context dose ranges studied across indication areas — framed as study parameters, not recommendations. The FAQ addresses the questions most commonly asked about Tα1's regulatory status, evidence base, and mechanism. The references page provides a complete citation list with PubMed and PMC links for every source used across the site. The about page describes this site's editorial methodology.

Every quantitative claim on this site cites a specific study from the published literature. Where findings are contested — as they are in sepsis — that contest is described with the same neutrality as the findings themselves.